Journal ArticleDOI
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Reads0
Chats0
TLDR
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.About:
This article is published in The Lancet.The article was published on 2019-07-13. It has received 1449 citations till now. The article focuses on the topics: Dulaglutide & Placebo-controlled study.read more
Citations
More filters
Journal ArticleDOI
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies,David A. D'Alessio,Judith E. Fradkin,Walter N. Kernan,Chantal Mathieu,Geltrude Mingrone,Peter Rossing,Apostolos Tsapas,Deborah J. Wexler,John B. Buse +9 more
TL;DR: A panel to update the prior position statements on the management of type 2 diabetes in adults includes additional focus on lifestyle management and diabetes self-management education and support and efforts targeting weight loss.
Journal ArticleDOI
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren,François Mach,Yvo M. Smulders,David Carballo,Konstantinos C. Koskinas,Maria Bäck,Athanase Benetos,Alessandro Biffi,José-Manuel Boavida,Davide Capodanno,Bernard Cosyns,Carolyn Crawford,Constantinos H. Davos,Ileana Desormais,Emanuele Di Angelantonio,Oscar H. Franco,Sigrun Halvorsen,FD Richard Hobbs,Monika Hollander,Ewa A. Jankowska,Matthias Michal,Simona Sacco,Naveed Sattar,Lale Tokgozoglu,Serena Tonstad,Konstantinos P Tsioufis,Ineke van Dis,Isabelle C. Van Gelder,Christoph Wanner,Bryan Williams,Guy De Backer,Vera Regitz-Zagrosek,Anne Hege Aamodt,Magdy Abdelhamid,Victor Aboyans,Christian Albus,Riccardo Asteggiano,Magnus Bäck,Michael A. Borger,Carlos Brotons,Jelena Čelutkienė,Renata Cifkova,Maja Čikeš,Francesco Cosentino,Nikolaos Dagres,Tine De Backer,Dirk De Bacquer,Victoria Delgado,Hester Den Ruijter,Paul Dendale,Heinz Drexel,Volkmar Falk,Laurent Fauchier,Brian A. Ference,Jean Ferrières,Marc Ferrini,Miles Fisher,Danilo Fliser,Zlatko Fras,Dan Gaita,Simona Giampaoli,Stephan Gielen,Ian D. Graham,Catriona Jennings,Torben Jørgensen,Alexandra Kautzky-Willer,Maryam Kavousi,Wolfgang Koenig,Aleksandra Konradi,Dipak Kotecha,Ulf Landmesser,Madalena Lettino,Basil S. Lewis,Aleš Linhart,Maja-Lisa Løchen,Konstantinos Makrilakis,Giuseppe Mancia,Pedro Marques-Vidal,John W. McEvoy,Paul McGreavy,Béla Merkely,Lis Neubeck,Jens Cosedis Nielsen,Joep Perk,Steffen E. Petersen,Anna Sonia Petronio,Massimo F Piepoli,Nana Pogosova,Eva Prescott,Kausik K. Ray,Zeljko Reiner,Dimitrios J. Richter,Lars Rydén,Evgeny Shlyakhto,Marta Sitges,Miguel Sousa-Uva,Isabella Sudano,Monica Tiberi,Rhian M. Touyz,Andrea Ungar,W. M. Monique Verschuren,Olov Wiklund,David A. Wood,José Luis Zamorano,Carolyn A Crawford,Oscar H Franco Duran +105 more
Journal ArticleDOI
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies,Melanie J. Davies,David A. D'Alessio,Judith E. Fradkin,Walter N. Kernan,Chantal Mathieu,Geltrude Mingrone,Geltrude Mingrone,Peter Rossing,Peter Rossing,Apostolos Tsapas,Deborah J. Wexler,John B. Buse +12 more
TL;DR: A panel to update the prior position statements on the management of type 2 diabetes in adults includes additional focus on lifestyle management and diabetes self-management education and support and efforts targeting weight loss.
Journal ArticleDOI
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Søren Lund Kristensen,Søren Lund Kristensen,Rasmus Rørth,Rasmus Rørth,Pardeep S. Jhund,Kieran F. Docherty,Naveed Sattar,David Preiss,Lars Køber,Mark C. Petrie,John J.V. McMurray +10 more
TL;DR: Overall, GLP-1 receptor agonist treatment reduced MACE by 12% and there was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer.
Journal ArticleDOI
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Dawn Kleindorfer,Amytis Towfighi,Seemant Chaturvedi,Kevin M. Cockroft,Jose Gutierrez,Debbie Lombardi-Hill,Hooman Kamel,Walter N. Kernan,Steven J. Kittner,Enrique C. Leira,Olive Lennon,James F. Meschia,Thanh N. Nguyen,Peter M. Pollak,Pasquale Santangeli,Anjail Sharrief,Sidney C. Smith,Tanya N. Turan,Linda S. Williams +18 more
References
More filters
Journal ArticleDOI
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
Journal ArticleDOI
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker,Stephen D. Wiviott,Itamar Raz,KyungAh Im,Erica L. Goodrich,Marc P. Bonaca,Ofri Mosenzon,Eri Toda Kato,Avivit Cahn,Remo H.M. Furtado,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc S. Sabatine +14 more
TL;DR: SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atheroscerotic cardiovascular disease, however, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerosis or a history of heart failure.
Journal ArticleDOI
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer,Brian Claggett,Rafael Diaz,Kenneth Dickstein,Hertzel C. Gerstein,Lars Køber,Francesca C. Lawson,Lin Ping,Xiaodan Wei,Eldrin F. Lewis,Aldo P. Maggioni,John J.V. McMurray,Jeffrey L. Probstfield,Matthew C. Riddle,Scott D. Solomon,Jean-Claude Tardif +15 more
TL;DR: In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events.